A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients
一项评估抗IFN-α单克隆抗体sifalimumab的1b期临床试验显示,该抗体能够靶向中和皮肌炎和多发性肌炎患者血液中的I型IFN特征。
期刊:Annals of the Rheumatic Diseases
影响因子:20.6
doi:10.1136/annrheumdis-2012-202794
Higgs, Brandon W; Zhu, Wei; Morehouse, Chris; White, Wendy I; Brohawn, Philip; Guo, Xiang; Rebelatto, Marlon; Le, Chenxiong; Amato, Anthony; Fiorentino, David; Greenberg, Steven A; Drappa, Jorn; Richman, Laura; Greth, Warren; Jallal, Bahija; Yao, Yihong